LipoCure is developing a number of therapeutics utilizing proprietary liposome-based nano drugs with novel drug-loading capabilities and drug-release mechanisms. LipoCure's proprietary platform implements an approach that allows for remote drug loading into nano-liposomes and concomitant controlled release of the drugs at the targeted site. This technology is designed to produce an enhanced permeability and retention effect, a significantly improved therapeutic effect, and reduced side effects. It can be used in conjunction with several well-established drugs used for the treatment of rheumatoid arthritis, multiple sclerosis, and cancer. LipoCure's founder is professor Yechezkel Barenholz, the co-developer of Doxil.